Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
Tam CS, Gregory GP, Ku M, Fleming S, Handunnetti SM, Lee D, Walker P, Perkins A, Lew TE, Sirdesai S, Chua CC, Gilbertson M, Lasica M, Anderson MA, Renwick W, Grigg A, Patil S, Opat S, Friebe A, Cooke R, De Boer J, Spencer A, Ritchie D, Agarwal R, Blombery P. Tam CS, et al. Among authors: patil s. Intern Med J. 2022 Jul;52(7):1286-1287. doi: 10.1111/imj.15851. Intern Med J. 2022. PMID: 35879233 No abstract available.
Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, Curtis DJ, Patil S, Das T, Klarica D, Morgan S, Muirhead J, Gorniak M, Reynolds J, Spencer A. Nair AP, et al. Among authors: patil s. Bone Marrow Transplant. 2017 Jun;52(6):839-845. doi: 10.1038/bmt.2017.37. Epub 2017 Mar 20. Bone Marrow Transplant. 2017. PMID: 28319080
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Bryant A, Nivison-Smith I, Pillai ES, Kennedy G, Kalff A, Ritchie D, George B, Hertzberg M, Patil S, Spencer A, Fay K, Cannell P, Berkahn L, Doocey R, Spearing R, Moore J. Bryant A, et al. Among authors: patil s. Bone Marrow Transplant. 2014 Jan;49(1):17-23. doi: 10.1038/bmt.2013.142. Epub 2013 Sep 23. Bone Marrow Transplant. 2014. PMID: 24056743
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
Patil S, Spencer A, Schwarer A, Lewis I, Hertzberg M, Avery S, Wei A, Noutsos T, Paul E, Taouk Y, Muirhead J. Patil S, et al. Bone Marrow Transplant. 2010 Jul;45(7):1154-60. doi: 10.1038/bmt.2009.322. Epub 2009 Nov 9. Bone Marrow Transplant. 2010. PMID: 19898502 Clinical Trial.
An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.
Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D'Souza AB, Ganly P, Ebeling P, Wong E. Grigg A, et al. Among authors: patil s. Bone Marrow Transplant. 2017 Sep;52(9):1288-1293. doi: 10.1038/bmt.2017.108. Epub 2017 Jun 19. Bone Marrow Transplant. 2017. PMID: 28628088 Clinical Trial.
5,318 results